Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C16H16ClNO3S.H2O4S |
| Molecular Weight | 435.9 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.COC(=O)[C@@H](N1CCC2SC(=O)C=C2C1)C3=C(Cl)C=CC=C3
InChI
InChIKey=UNHVSUGSGIXYQF-LDCKTULKSA-N
InChI=1S/C16H16ClNO3S.H2O4S/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13;1-5(2,3)4/h2-5,8,13,15H,6-7,9H2,1H3;(H2,1,2,3,4)/t13?,15-;/m0./s1
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C16H16ClNO3S |
| Molecular Weight | 337.821 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19122335
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19122335
Clopidogrel is first activated to its thiolactone intermediate, 2-oxo-clopidogrel via CYP3A oxidation. 2-oxo-clopidogrel is a key intermediate metabolite from which the active metabolite is formed. 2-oxo-clopidogrel inhibited the activity of CYP2C19 and moderately activity of CYP2B6.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL3622 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19122335 |
0.995 µM [IC50] | ||
Target ID: CHEMBL4729 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19122335 |
1.3 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. | 2012-02-20 |
|
| Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. | 2010-01 |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12386137
2-oxo-clopidogrel (SR121682) is the essential key intermediate metabolite from which the active metabolite is formed. This was approved using enzymatic assay with human liver microsomes. SR121682 was added at a final concentration of 0.1 mM, and the reaction was initiated with 1 mM NADPH
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 00:21:34 GMT 2025
by
admin
on
Wed Apr 02 00:21:34 GMT 2025
|
| Record UNII |
R98IO5OIG5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
R98IO5OIG5
Created by
admin on Wed Apr 02 00:21:34 GMT 2025 , Edited by admin on Wed Apr 02 00:21:34 GMT 2025
|
PRIMARY | |||
|
72206114
Created by
admin on Wed Apr 02 00:21:34 GMT 2025 , Edited by admin on Wed Apr 02 00:21:34 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY | |||
|
|
ACTIVE MOIETY |